Diagnosis and Phenotype Characterisation Using Genomics in Patients With Inherited Bone Marrow Failure (IBMDx Study)
Launched by PETER MACCALLUM CANCER CENTRE, AUSTRALIA · Jan 4, 2022
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
The IBMDx Study is a clinical trial aimed at understanding inherited bone marrow failure syndromes (IBMF) and related conditions by analyzing the genetic information of patients. Researchers will use advanced techniques to look closely at the DNA and gene activity of 350 individuals who may have these disorders. The goal is to improve the ability to diagnose these conditions, which can lead to better treatment options for patients.
To participate in this study, individuals must be at least 3 months old and either able to provide their own consent or have a parent or guardian who can do so. They should have a diagnosis or suspected diagnosis of an inherited bone marrow failure syndrome or a related disorder. However, people with acquired forms of bone marrow failure or those who already have a clear genetic diagnosis for their condition will not be eligible. Participants can expect to undergo genetic testing, and their information may help advance the understanding of these conditions for future patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. age ≥ 3 months
- • 2. able to give informed consent (or parent/guardian able to give informed consent)
- • 3. a clinicopathological diagnosis (or differential diagnosis) of inherited bone marrow failure syndrome or related disorder (IBMFS-RD) as per the study team
- Exclusion Criteria:
- • 1. A clinicopathological diagnosis of an acquired bone marrow failure syndrome (including acquired aplastic anaemia and hypoplastic myelodysplastic syndrome) as per the study team
- • 2. Existing definitive genomic diagnosis for patient's haematological phenotype
About Peter Maccallum Cancer Centre, Australia
Peter MacCallum Cancer Centre, located in Australia, is a leading global cancer research, education, and treatment facility. Renowned for its innovative approach to cancer care, the center integrates cutting-edge research with clinical practice to improve patient outcomes. With a commitment to advancing cancer therapies, Peter MacCallum conducts a wide range of clinical trials that explore novel treatment modalities, aiming to enhance understanding of cancer biology and optimize therapeutic strategies. The institution is dedicated to fostering collaboration among researchers, clinicians, and patients to drive progress in cancer treatment and prevention.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Melbourne, Victoria, Australia
Patients applied
Trial Officials
Piers Blombery, MBBS(Hons)
Principal Investigator
Peter MacCallum Cancer Centre, Australia
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials